[New protease inhibitor for PI pretreated patients. Tipranavir targets also multiresistant viruses].
D018791:CD4 Lymphocyte Count; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D024921:Drug Resistance, Multiple, Viral / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides; D016896:Treatment Outcome; D019562:Viral Load
D003692:Delayed-Action Preparations; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir
Neuer Proteaseinhibitor für PI-erfahrene Patienten. Tipranavir trifft auch multiresistente Viren.